FDA Approves New Treatment for Type 2 Diabetes

Tradjenta was demonstrated to be safe and effective in eight clinical studies involving about 3,800 patients with Type 2 diabetes.

The U.S. FDA Monday approved Tradjenta (linagliptin) tablets, used with diet and exercise, to improve blood glucose control in adults with Type 2 diabetes.

Type 2 diabetes is the most common form of the disease, affecting between 90 percent and 95 percent of the 24 million people in the United States with diabetes. Tradjenta increases the level of hormones that stimulate the release of insulin after a meal by blocking the enzyme dipeptidyl peptidase-4 or DPP-4, which leads to better blood glucose control.